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COMPARATIVE EFFECTIVENESS REVIEW: DRUG-ELUTING STENTS 
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OBJECTIVES: To estimate the relative impact of drug-eluting stents(DES) versus 
bare-metal stents(BMS) on death, myocardial infarction(MI), target vessel revasculari-
zation(TVR), and stent thrombosis(ST) in patients with ST-elevation acute myocardial 
infarction(STEMI) by performing comprehensive meta-analyses of randomized con-
trolled trials(RCTs) and observational studies METHODS: We searched Ovid-
Medline, EMBASE, the Cochrane Library, and conference proceedings for articles 
comparing outcomes between DES and BMS among STEMI patients presented 
through September 2009. The quality of studies was evaluated by using the Cochrane’s 
risk of bias for RCTs and MINORS(Methodological Index for Non-Randomized 
Studies) for observational studies. The relative risk(RR) using the inverse variance 
random-effects method for each study outcome was calculated. RCT and observa-
tional data were analyzed separately. To assess heterogeneity of RRs across trials, we 
used the Cochrane-Q-statistic and I2-statistic. Subgroup-analyses were performed by 
length of follow-up and meta-regression was used to evaluate predictors of outcomes 
by stent-type. Funnel plots, the Egger-test, and the Begg-test were used to assess 
publication-bias. To assess the quality of the evidence, we used GRADEpro.RESULTS: 
Fifteen RCTs were identiﬁed(N = 7654, kappa-statistic = 0.90). Compared with BMS, 
DES signiﬁcantly reduced TVR(RR:0.48; 95% conﬁdence interval[CI]:0.41–0.56) and 
MI(RR:0.76; 95%CI:0.60–0.96), without increasing death(RR = 0.88; 95%CI:0.70–
1.11) and ST(RR:0.93; 95%CI:0.72–1.21). Among 35 observational studies(N = 
44,849), DES signiﬁcantly reduced death(RR:0.85; 95%CI:0.79–0.91) and 
TVR(RR:0.61; 95%CI:0.48–0.77). MI and ST were signiﬁcantly lower in the DES 
group within 1-year follow-up, but there were no differences within 2-years follow-up. 
There was no evidence of statistical heterogeneity and publication-bias. Among RCTs, 
the quality of the evidence of TVR was assessed as “High”, death and MI as “moder-
ate”, and ST as “low”. The quality of the evidence from observational studies was 
assessed as “very low” or “low”. CONCLUSIONS: These data in aggregate suggest 
that using DES in STEMI patients are safe and efﬁcacious but there are differences 
between RCT and observational data comparing DES and BMS.
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BELIEFS ABOUT ANTIHYPERTENSIVE MEDICATIONS IN PRIMARY 
CARE PATIENTS: VALIDATION OF BELIEFS ABOUT MEDICINES 
QUESTIONNAIRE (BMQ) IN COLOMBIA
Garcia Vega OA, Buendia Rodriguez JA
Universidad Nacional de Colombia, Bogota, Colombia
OBJECTIVES: determinate the factor structure of the Beliefs about Medicines Ques-
tionnaire (BMQ) and examine the association of medication beliefs with medication 
adherence METHODS: Seventeen patients who used antihypertensive drugs partici-
pated in semi-standardized interviews. Interviews were recorded and reviewed by two 
investigators. The medication adherence was measured using the method of count of 
tablets. An exploratory factor analysis was performed. Multiple linear regression was 
used to determine whether beliefs about medications were signiﬁcantly associated with 
medication adherence RESULTS: Factor analysis resulted in a two solution, explaining 
46.7% of cumulative variance among respondents. The factors were labeled: Overuse 
(Concerns about the way doctors use medications) and Harm (Beliefs that medications 
are harmful). Chronbach’s alpha coefﬁcient was 0.71. Beliefs about medications 
(Overuse and Harm) were signiﬁcantly associated with non-adherence to antihyper-
tensive drugs CONCLUSIONS: The factorial structure of BMQ was similar than 
previously reported in other medical conditions. Also these ﬁndings suggest that in 
addition to telling patients how to take their medications, primary care physicians 
should educate patients about short and long-term effects of the medication and all 
possible therapeutic alternatives to improve the adherence to antihypertensive 
medication.
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DERIVING DOCTORS’ PRESCRIBING PATTERNS FROM CLAIMS DATA: 
AN APPLICATION TO ANTICOAGULANT USE IN PATIENTS WITH 
NON-VALVULAR ATRIAL FIBRILLATION
Wang L1, Gust C1, Baser O2
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research / University of 
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OBJECTIVES: Doctors’ practice and prescribing patterns are based on many factors, 
some of which are not observable. We derived doctors’ prescribing patterns from U.S. 
claims data to show how it might be related with decisions on anticoagulant use for 
venous thromboembolism (VTE) treatment. METHODS: Based on U.S. claims data, 
we assigned doctors IDs based on the physician who treated the enrollee for the longest 
period of time after eliminating any emergency room, laboratory, and radiology ser-
vices. Physician prescribing patterns were then calculated from prescription drug 
records. Patients were grouped as compliant and non-compliant to warfarin. 
RESULTS: We identiﬁed the doctors’ prescribing pattern with the percentage of time 
they prescribed warfarin, injectable anticoagulation, antiplatelet, anti-arrhythmics, 
rate control drugs and other drugs. We showed that patients were more likely to be 
compliant to warfarin if their physician’s prescribing pattern favored warfarin. 
Patients were less compliant if their physician’s prescribing pattern favored injectable 
anticoagulation or antiplatelet. There were no effects on compliance if doctors’ pre-
scribing patterns favored anti-arrhythmics or rate control drugs. CONCLUSIONS: 
Doctors’ prescribing patterns are important factors for patient compliance. Therefore, 
failing to control for these patterns in compliance models might lead to omitted vari-
able bias.
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OBJECTIVES: To examine whether there was a change in statin use patterns after 
release of results from the JUPITER study using a nationally-representative Electronic 
Medical Record (EMR) database. METHODS: The EMR database reviewed was the 
Medical Quality Improvement Consortium (MQIC) database from GE. This database 
contains EMR data collected from over 11,000 ambulatory providers in the United 
States and includes over 12 million patients as of April, 2009. Records were reviewed 
for the total database before and four months after. Among adults ≥ 18 years of age, 
new statin usage (4 months before and after) and switches involving rosuvastatin, the 
statin in the JUPITER study, were counted. RESULTS: Of over 9.4 million adults, 
over 1.2 million (13%) are recorded as taking a statin. The proportion of statin usage 
remained consistent before and 4 months after JUPITER with percentage of use among 
the patients as follows: rosuvastatin (11%), simvastatin (32%), atorvastatin (49%), 
other statins (27%), or a recently approved statin/ezetimibe (11%) combination 
product (percents add to more than 100 as patients may be on more than one product). 
When comparing the proportion of reported new statin usage 4 months pre/post 
JUPITER among the new statin users, there is an increase in simvastatin, from 26% 
to 29%, with other statins showing slight decreases in that time period. CONCLU-
SIONS: Although JUPITER is already considered a seminal study by many, it has not 
yet impacted clinical practice, suggesting a time lag in getting evidence into practice. 
This EMR database provides a valuable data source to monitor real-time, real-world 
prescribing practices, and will permit further exploration of relevant patient charac-
teristics, such as CRP and LDL levels, and outcomes that is not possible using admin-
istrative datasets.
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STATIN USE BEFORE AND AFTER CABG PROCEDURE
Iyer RG, Matlin O
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OBJECTIVES: Statin therapy has been shown to reduce disease progression following 
coronary artery bypass graft procedure (CABG). Recommendations include low-fat 
diet and cholesterol-lowering medications after bypass surgery to reduce subsequent 
graft attrition. The objectives of the study were to 1) examine the percent of par-
ticipants who were prescribed a statin within a month post CABG procedure 2) 
identify predictors of statin use post CABG METHODS: Participants with CABG 
anytime during 2003–2008 and their statin use pre-post CABG were identiﬁed using 
de-identiﬁed administrative medical claims and administrative pharmacy claims 
respectively. Date of CABG was considered the index date for the study analysis. 
The variables to predict a new script for statin included use of statin before CABG, 
age, gender, physician specialty, other co-morbidities, and the number of other 
medications. A logistic regression was used to estimate the likelihood of statin uti-
lization post CABG. RESULTS: The study cohort consisted of 10,418 patients who 
underwent CABG during the study period. The mean age of the cohort was 70.3 
± 11.2 years, and 75% of the patients were male. During the 1-year period before 
CABG surgery, 40% of patients utilized prescription statin therapy. 47% of patients 
ﬁlled a statin prescription within 1 month of CABG procedure. 24% of the patients 
did not have prescription claims for statins any time post CABG. The likelihood of 
ﬁlling a prescription for statin post CABG was 5.51 (95% CI: 4.89–6.21) higher in 
patients who utilized a statin prior to CABG. Males were 1.36 times more likely 
to utilize a statin than females (95% CI: 1.22–1.51) CONCLUSIONS: A signiﬁcant 
proportion of patients do not utilize statins after CABG, missing effective drug 
therapy. The use of statin before CABG is a signiﬁcant predictor of statin use 
post-CABG.
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NOVEL QUALITY ASSURANCE ANALYSIS REVEALS PREVIOUSLY 
UNDETECTED DEFICIENCIES IN A POINT OF CARE DEVICE THAT 
MEASURES THE INTERNATIONAL NORMALIZED RATIO
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OBJECTIVES: Measures used to make clinical decisions are assessed by quality assur-
ance (QA) programs. Our group’s research suggests standard QA analyses can fail to 
provide relevant clinical information and may be misleading. We compared a novel 
clinically-based QA analysis to previously conducted standard QA analysis of INR 
measures by point-of-care (POC) devices in our anticoagulation clinics. METHODS: 
Previously analyzed QA data, collected January, 2006 through June, 2008 were 
obtained. Two INR samples were obtained from each patient at the same anticoagula-
tion clinic visit: one venous sample analyzed by our core laboratory (considered the 
